Back to the main directory
Press Release
- EQS-News: CureVac geht in Phase 2 der laufenden saisonalen Grippestudie in Zusammenarbeit mit GSK nach Auswahl eines vielversprechenden mRNA-Impfstoffkandidaten mit breiter Abdeckung by EQS Group AG
- Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023 by GlobeNewsWire
- Energy Recovery Establishes Corporate Emissions Reduction Target; Surpasses $5.9 Billion in Energy Savings for Customers According to Latest Sustainability Report by BusinessWire
- Banco Comercial Português, S.A. informs about the upgrade to Investment Grade of senior debt ratings by S&P Global by GlobeNewsWire
- Opjustering af resultatforventning for regnskabsåret 2022/23 by GlobeNewsWire
- RE+ 2023: SolarEdge Launches its Most Powerful Ground-Mount Solution, Targeting U.S. Community Solar and Small-Medium Utility by BusinessWire
- The Nomura Trust & Banking Co., Ltd. Successfully Goes Live on the nCino Cloud Banking Platform by GlobeNewsWire
- The Nomura Trust & Banking Co., Ltd. Successfully Goes Live on the nCino Cloud Banking Platform by GlobeNewsWire
- Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results by GlobeNewsWire
- Anavex Announces Appointment of Dr. Marwan N Sabbagh, MD as Chairman of the Scientific Advisory Board by GlobeNewsWire
- Abeona Therapeutics Appoints Madhav Vasanthavada, Ph.D., M.B.A. as Chief Commercial Officer by GlobeNewsWire
- Les Thés DAVIDsTEA publient leurs résultats financiers du deuxième trimestre de l’exercice 2023 by GlobeNewsWire
- Christina Lake Closes First Tranche of Non-Brokered Private Placement of Secured Convertible Notes by GlobeNewsWire
- Repligen Appoints Jason K. Garland as Chief Financial Officer by GlobeNewsWire
- GURU Organic Energy Launches ’Feel Good Energy Challenge’ With Renowned Host and NBA Rookie Player Gradey Dick by GlobeNewsWire
- PyroGenesis Signs $2.25 Million Plasma Torch Contract for PFAS Removal by GlobeNewsWire
- Arcutis Submits Roflumilast Cream 0.15% Supplemental New Drug Application to the FDA for the Treatment of Atopic Dermatitis in Adults and Children Ages 6 Years and Older by GlobeNewsWire
- Bombardier Ranks Among Top 30 on Toronto Stock Exchange, Recognized for Impressive Share Performance by GlobeNewsWire
- Kane Biotech Announces Closing of Fully Subscribed Private Placement Offering and Amendments to its Credit Facility by GlobeNewsWire
- Form 8.3 - The Vanguard Group, Inc.: Horizon Therapeutics plc by EQS Group AG
- Revolution in der Entdeckung von Impfstoffen: Neue Daten validieren die KI-Plattform von Evaxion und versprechen Senkung der Risiken und Kosten bei der Entwicklung von Impfstoffen gegen Infektionskrankheiten by GlobeNewsWire
- Rovio Entertainment Corp.: Decisions of the Extraordinary General Meeting and the organizing meeting of the Board of Directors by GlobeNewsWire
- Ceridian Strengthens Climate Strategy with SBTi Commitment and Scope 3 Emissions Reduction Target by GlobeNewsWire
- Jet.AI on Pace to Release Operator Platform and Four Software Features by Year End by GlobeNewsWire
- TransUnion Research Shows Seven in 10 Consumers Miss Legitimate Phone Calls Due to Fear of Robocalls, Call Spoofing and Fraud by GlobeNewsWire